The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .
Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation
The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric in patients . This was a naturalistic , retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital . To be included , patients had to be < 18 years of age and treated with aripiprazole for at least two consecutive weeks during their hospital stay . We used a chart extracted Clinical Global Impression of Improvement , and a chart extracted Clinical Global Impression of Severity of Illness score to determine their effectiveness . Adverse events and side effects recorded in the physician or nursing notes were collected to establish tolerability . Forty-five patients met the criteria and were included in this analysis . Average clinical global impression of severity of illness scores at baseline and endpoint were 5.04±0.91 and 3.33±1.24 respectively . This difference was statistically significant ( Wilcoxon 's signed-rank test : Z=−5.179 , P<0.001 ) . Fifty-one percent of the youth had a clinical global impression of severity of illness score that was much improved or very much improved ( clinical global impression of improvement score of 1 or 2 ) . Significant reduction in clinical global impression of severity of illness scores suggests a decline in the symptom severity for patients treated with aripiprazole . On the basis of the reported adverse events and side effects , aripiprazole was generally well tolerated . R and omized controlled trials of aripiprazole in childhood mental disorders are warranted
The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .